CA
NZ
UK
AU
IND
US
…
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Immatics NV is a clinical-stage biotechnology company developing T‑cell receptor (TCR)-based cancer therapies and TCR bispecifics using a proprietary target-discovery platform to identify tumor peptide‑HLA targets. Long-term growth drivers include clinical advancement of its pipeline across multiple tumor antigens and platform-driven target expansion, which could appeal to investors seeking exposure to next-generation TCR immunotherapies.
Primary investment risks are high clinical and regulatory uncertainty, manufacturing complexity, and potential need for substantial additional capital to advance programs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -198.44M | 21.35M | -96.99M | 42.04M | -93.33M |
| Minority interest | - | - | - | 0.00M | 0.00M |
| Net income | -196.45M | 15.22M | -94.65M | 37.51M | -95.06M |
| Selling general administrative | 51.18M | 46.45M | 38.20M | 36.12M | 33.81M |
| Gross profit | 48.27M | 155.84M | 54.00M | 172.83M | 34.76M |
| Reconciled depreciation | 12.40M | 12.22M | 7.23M | 6.97M | 5.26M |
| Ebit | -197.49M | 22.23M | -96.16M | 29.95M | -86.29M |
| Ebitda | -185.09M | 34.46M | -88.93M | 46.34M | -75.36M |
| Depreciation and amortization | 12.40M | 12.22M | 7.23M | 16.38M | 10.94M |
| Operating income | -182.02M | -38.62M | -101.72M | 29.95M | -86.29M |
| Other operating expenses | 230.28M | 194.45M | 155.72M | 142.88M | 121.05M |
| Interest expense | 0.95M | 0.89M | 0.83M | 8.28M | 1.73M |
| Tax provision | -1.99M | 6.13M | -2.35M | 4.52M | 0.00M |
| Interest income | 17.18M | 25.00M | 13.85M | 2.48M | 5.67M |
| Net interest income | 16.23M | 24.11M | 13.01M | 1.44M | 3.95M |
| Income tax expense | -1.99M | 6.13M | -2.35M | 4.55M | 1.73M |
| Total revenue | 48.27M | 155.84M | 54.00M | 172.83M | 34.76M |
| Total operating expenses | 230.28M | 194.45M | 155.72M | 142.88M | 121.05M |
| Cost of revenue | - | 148.08M | 118.66M | - | - |
| Total other income expense net | -16.42M | 59.96M | 4.73M | 12.08M | -7.04M |
| Net income from continuing ops | -196.45M | 15.22M | -96.99M | 37.51M | -93.33M |
| Net income applicable to common shares | - | - | - | 37.51M | -93.33M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 562.10M | 696.15M | 509.96M | 407.82M | 174.65M |
| Intangible assets | 1.58M | 1.63M | 1.52M | 1.63M | 1.31M |
| Other current assets | 27.78M | 18.36M | 7.12M | 13.84M | 6.41M |
| Total liab | 78.20M | 121.30M | 284.88M | 194.66M | 150.58M |
| Total stockholder equity | 483.89M | 574.84M | 225.08M | 213.16M | 24.06M |
| Other current liab | 24.09M | 15.35M | 45.88M | 26.28M | 30.41M |
| Common stock | 1.34M | 1.22M | 0.85M | 0.77M | 0.63M |
| Capital stock | 1.34M | 1.22M | 0.85M | 0.77M | 0.63M |
| Retained earnings | -785.65M | -589.54M | -597.29M | -500.30M | -537.81M |
| Other liab | - | - | - | - | 48.29M |
| Other assets | - | - | - | 2.54M | 0.64M |
| Cash | 345.77M | 236.75M | 218.47M | 148.52M | 132.99M |
| Total current liabilities | 42.99M | 67.99M | 156.55M | 106.45M | 95.15M |
| Current deferred revenue | 15.81M | 35.91M | 100.40M | 64.96M | 50.40M |
| Net debt | -330.14M | -220.54M | -203.07M | -133.96M | -123.14M |
| Short term debt | 2.76M | 2.85M | 2.60M | 2.16M | 2.71M |
| Short long term debt total | 15.63M | 16.20M | 15.40M | 14.56M | 9.85M |
| Other stockholder equity | 1276.79M | 1162.14M | 823.17M | 714.18M | 565.19M |
| Property plant equipment | - | - | - | 26.49M | 20.49M |
| Total current assets | 503.79M | 629.55M | 449.37M | 377.15M | 152.21M |
| Net tangible assets | - | - | - | 211.53M | 22.75M |
| Short term investments | 123.37M | 367.70M | 207.42M | 213.69M | 12.12M |
| Net receivables | 6.88M | 6.75M | 5.74M | 1.11M | 0.68M |
| Inventory | - | - | 10.62M | - | - |
| Accounts payable | 0.34M | 10.11M | 7.67M | 13.06M | 11.62M |
| Accumulated other comprehensive income | -8.59M | 1.03M | -1.64M | -1.48M | -3.94M |
| Non currrent assets other | 1.85M | 1.25M | 2.02M | 2.54M | 0.64M |
| Non current assets total | 58.30M | 66.59M | 60.59M | 30.67M | 22.44M |
| Capital lease obligations | 15.63M | 16.20M | 15.40M | 14.56M | 9.85M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 211.59M | -152.39M | -31.39M | -209.79M | 13.15M |
| Change to liabilities | - | - | - | 45.56M | -31.78M |
| Total cashflows from investing activities | 196.70M | -152.39M | -31.39M | -209.79M | 7.49M |
| Net borrowings | -2.96M | -2.01M | -3.85M | -2.84M | -2.71M |
| Total cash from financing activities | 93.51M | 319.68M | 84.52M | 123.71M | -2.61M |
| Change to operating activities | - | - | - | -7.87M | -0.48M |
| Net income | -188.69M | 15.22M | -94.65M | 37.51M | -93.33M |
| Change in cash | 137.12M | 18.28M | 69.95M | 15.53M | -74.54M |
| Begin period cash flow | 208.65M | 218.47M | 148.52M | 132.99M | 207.53M |
| End period cash flow | 345.77M | 236.75M | 218.47M | 148.52M | 132.99M |
| Total cash from operating activities | -169.66M | -158.03M | 18.23M | 100.13M | -81.78M |
| Issuance of capital stock | 107.31M | 343.01M | 90.40M | 134.48M | 0.09M |
| Depreciation | 11.91M | 12.22M | 7.23M | 6.97M | 5.26M |
| Other cashflows from investing activities | - | -0.21M | -0.01M | - | - |
| Change to inventory | - | - | -84.24M | - | - |
| Change to account receivables | -0.23M | -1.76M | -2.98M | -0.43M | 0.57M |
| Other cashflows from financing activities | -2.84M | -21.31M | -2.04M | -7.93M | 7.49M |
| Change to netincome | - | - | - | 18.39M | 37.99M |
| Capital expenditures | 6.30M | 16.48M | 30.96M | 6.21M | 5.66M |
| Change in working capital | -42.23M | -163.88M | 81.63M | 37.26M | -31.70M |
| Stock based compensation | 15.02M | 17.64M | 20.70M | 22.57M | 26.40M |
| Other non cash items | 49.36M | -45.37M | 3.31M | -8.70M | 0.43M |
| Free cash flow | -175.95M | -174.51M | -12.73M | 93.92M | -87.44M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IMTX Immatics NV |
-0.19 2.84% |
6.50 | - | - | 31.39 | 2.83 | 18.06 | 7.19 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
| Name | Title | Year Born |
|---|---|---|
| Dr. Harpreet Singh Ph.D. | CEO, MD, Member of Management Board & Supervisory Director | 1975 |
| Dr. Hans-Georg Rammensee Ph.D. | Co-Founder & Member of the Scientific Advisory Board | NA |
| Dr. Toni Weinschenk Ph.D. | Co-Founder & Chief Innovation Officer | 1973 |
| Mr. Arnd Christ MBA | Chief Financial Officer | 1966 |
| Mr. Steffen Walter Ph.D. | Chief Technology Officer | 1976 |
| Mr. Edward A. Sturchio | Gen. Counsel & Sec. | NA |
| Ms. Anja Heuer B.Sc. | Director of Corp. Communications | NA |
| Ms. Tamara Louw M.B.A., P.H.R. | Sr. Director of HR | NA |
| Dr. Carsten Reinhardt M.D., Ph.D. | Chief Devel. Officer | 1967 |
| Dr. Rainer Kramer Ph.D. | Chief Bus. Officer & Site Head Munich | 1965 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...